drug
eculizumab
Marketedupdated 6mo agoby Alexion Pharmaceuticals Inc
Approvedannual revenue · 2024–2024peak $3.1B
community read0 votes
🐶 often sniffed alongside
top 6all catalysts(0)
nothing on the calendar yet
Trials studying eculizumab
- phase3A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
- phase3Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
- phase3A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
- phase2Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris
- phase3A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
- —Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
- phase3Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
- phase3A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
News(1)
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that